



1233 Rec'd PCT/PTO 17 JAN 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Haagmans, et al.	Examiner:	Unassigned
Serial No.:	10/552,755	Group Art Unit:	Unassigned
Confirmation No:	Unassigned	Docket:	294-230 PCT/US
Filed:	October 11, 2005	Dated:	January 11, 2006
For:	SARS		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

*I hereby certify this correspondence is being deposited  
with the United States Postal Service as first class mail,  
postpaid in an envelope, addressed to:  
Commissioner for Patents, P.O. Box 1450,  
Alexandria, Virginia 22313-1450  
on January 11, 2006*

Signed: *Diana J. Gueira*

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R.

§1.56, Applicants submit herewith the following Information Disclosure Statement in  
accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

FOREIGN PATENT DOCUMENT

<u>COUNTRY</u>	<u>PATENT NO.</u>	<u>PUBLICATION DATE</u>
PCT	WO 03/013599 A2	February 20, 2003
EP	0 278 541	August 17, 1988

**NON-PATENT PUBLICATIONS**

1. Poutanen, et al., "Identification of Severe Acute Respiratory Syndrome in Canada", *New England Journal of Medicine*, 2003, 348:1995-2005.
2. Centers for Disease Control and Prevention, "Update: Outbreak of Severe Acute Respiratory Syndrome -- Worldwide 2003", *MMWR Weekly* 2003, 52(12):241-248.
3. Database EMBL, Jones, S., "The Complete Genome of the SARS Associated Coronavirus", *Genome Sciences Centre* 2003, Database Accession No. AY274119.
4. Snijder, et al., "Unique and Conserved Features of Genome and Proteome of SARS-coronavirus, an Early Split-off From the Coronavirus Group 2 Lineage", *J. Mol. Biol.* (2003), 331:991-1004.
5. Peiris, et al., "Coronavirus as a Possible Cause of Severe Acute Respiratory Syndrome", *The Lancet* 2003, 361:1319-1325.
6. Gerberding, Julie Louise, "Faster... but Fast Enough? Responding to the Epidemic of Severe Acute Respiratory Syndrome", *New England Journal of Medicine* 2003, 348:2030-2031.

7. Pei, et al. "Chicken Interferon Type I Inhibits Infectious Bronchitis Virus Replication and Associated Respiratory Illness", *Journal of Interferon and Cytokine Research* 2001, 21:1071-1077.
8. Smith, et al., "Intranasally Administered Alpha/beta Interferon Prevents Extension of Mouse Hepatitis Virus, Strain JHM, into the Brains of BALB/cByJ Mice", *Antiviral Research* 1987, 8:239-246.
9. Turner, et al., "Prevention of Experimental Coronavirus Colds with Intranasal  $\alpha$ -2b Interferon", *The Journal of Infectious Diseases* 1986, 154(3):443-447.
10. Haagmans, et al., "Pegylated Interferon-  $\alpha$  protects type 1 Pneumocytes against SARS Coronavirus Infection in Macaques", *Nature Medicine* 2004, 10(3):290-293.
11. Calder, Douglas., "Viragen Files Patent Application For Drug to Target SARS", Viragen, Inc. (2003).
12. Ströher, et al. "Severe Acute Respiratory Syndrome -- Related Coronavirus is Inhibited by Interferon-  $\alpha$ ", *JID* 2004, 189:1164-1167.
13. Kurlan, Vinson, "Can Coconut Drive SARS to Nuts?" *Business Line* (2003).

Applicant(s): Haagmans, et al.  
Serial No.: 10/552,755  
Filing Date: October 11, 2005  
Page 4 of 4


14. Masci, et al., "New and Modified Interferon Alfas: Preclinical and Clinical Data",  
*Current Oncology Reports* 2003, 5:108-113.

Copies of the cited references are enclosed to facilitate reference to them.

A listing of all the references has been set forth on the enclosed form PTO-1449. The Examiner is respectfully requested to consider these references in their entirety, and to indicate that he or she has done so by initialing the enclosed Patent and Trademark Office Form 1449.

If the Examiner has any questions relating to the present communication he or she is invited to contact Applicant's agent at the telephone number set forth below.

Respectfully submitted,

  
Edna I. Gergel, Ph.D.  
Registration No.: 50,819  
Agent for Applicant(s)

HOFFMANN & BARON, LLP  
6900 Jericho Turnpike  
Syosset, New York 11791  
(516) 822-3550  
EIG:dlg  
215667\_1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
294-230 PCT/US

SERIAL NO.  
10/552,755

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICANT  
Haagmans, et al.

CONFIRMATION NO.  
Unassigned

(Use several sheets if necessary)

FILING DATE  
October 11, 2005

GROUP  
Unassigned



FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO
	WO 03/013599 A2	February 20, 2003	PCT				
	0 278 541	August 17, 1988	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		1	Poutanen, et al., "Identification of Severe Acute Respiratory Syndrome in Canada", <i>New England Journal of Medicine</i> , 2003, 348:1995-2005.
		2	Centers for Disease Control and Prevention, "Update: Outbreak of Severe Acute Respiratory Syndrome -- Worldwide 2003", <i>MMWR Weekly</i> 2003, 52(12):241-248.
		3	Database EMBL, Jones, S., "The Complete Genome of the SARS Associated Coronavirus", <i>Genome Sciences Centre</i> 2003, Database Accession No. AY274119.
		4	Snijder, et al., "Unique and Conserved Features of Genome and Proteome of SARS-coronavirus, an Early Split-off From the Coronavirus Group 2 Lineage", <i>J. Mol. Biol.</i> (2003), 331:991-1004.
		5	Peiris, et al., "Coronavirus as a Possible Cause of Severe Acute Respiratory Syndrome", <i>The Lancet</i> 2003, 361:1319-1325.
		6	Gerberding, Julie Louise, "Faster... but Fast Enough? Responding to the Epidemic of Severe Acute Respiratory Syndrome", <i>New England Journal of Medicine</i> 2003, 348:2030-2031.
		7	Pei, et al. "Chicken Interferon Type I Inhibits Infectious Bronchitis Virus Replication and Associated Respiratory Illness", <i>Journal of Interferon and Cytokine Research</i> 2001, 21:1071-1077.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 294-230 PCT/US	SERIAL NO. 10/552,755
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Haagmans, et al.	CONFIRMATION NO. Unassigned
(Use several sheets if necessary)	FILING DATE October 11, 2005	GROUP Unassigned

		8	Smith, et al., "Intranasally Administered Alpha/beta Interferon Prevents Extension of Mouse Hepatitis Virus, Strain JHM, into the Brains of BALB/cByJ Mice", <i>Antiviral Research</i> 1987, 8:239-246.
		9	Turner, et al., "Prevention of Experimental Coronavirus Colds with Intranasal $\alpha$ -2b Interferon", <i>The Journal of Infectious Diseases</i> 1986, 154(3):443-447.
		10	Haagmans, et al., "Pegylated Interferon- $\alpha$ protects type 1 Pneumocytes against SARS Coronavirus Infection in Macaques", <i>Nature Medicine</i> 2004, 10(3):290-293.
		11	Calder, Douglas., "Viragen Files Patent Application For Drug to Target SARS", Viragen, Inc. (2003).
		12	Ströher, et al. "Severe Acute Respiratory Syndrome -- Related Coronavirus is Inhibited by Interferon- $\alpha$ ", <i>JID</i> 2004, 189:1164-1167.
		13	Kurlan, Vinson, "Can Coconut Drive SARS to Nuts?" Business Line (2003).
		14	Masci, et al., "New and Modified Interferon Alfas: Preclinical and Clinical Data", <i>Current Oncology Reports</i> 2003, 5:108-113.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.